711 reports of this reaction
2.5% of all LOPINAVIR AND RITONAVIR reports
#7 most reported adverse reaction
ANXIETY is the #7 most commonly reported adverse reaction for LOPINAVIR AND RITONAVIR, manufactured by AbbVie Inc.. There are 711 FDA adverse event reports linking LOPINAVIR AND RITONAVIR to ANXIETY. This represents approximately 2.5% of all 28,252 adverse event reports for this drug.
Patients taking LOPINAVIR AND RITONAVIR who experience anxiety should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANXIETY is a less commonly reported adverse event for LOPINAVIR AND RITONAVIR, but still significant enough to appear in the safety profile.
In addition to anxiety, the following adverse reactions have been reported for LOPINAVIR AND RITONAVIR:
The following drugs have also been linked to anxiety in FDA adverse event reports:
ANXIETY has been reported as an adverse event in 711 FDA reports for LOPINAVIR AND RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANXIETY accounts for approximately 2.5% of all adverse event reports for LOPINAVIR AND RITONAVIR, making it a notable side effect.
If you experience anxiety while taking LOPINAVIR AND RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.